An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Sponsor
UCB Biopharma SRL
Study ID
NCT06668181
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Enthesitis-related Arthritis
  • Juvenile Psoriatic Arthritis

Eligibility Criteria

Sex
ALL
Age
2 Years - 18 Years
Healthy Volunteers
Not accepted

Interventions

  • Bimekizumab — DRUG
    Bimekizumab will be administered at pre-specified timepoints.

Study Details

The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.

Key Dates

Start date
Mar 11, 2025
Status verified
Jun 2026
Primary completion
Apr 12, 2028
Completion
Jul 31, 2030

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bimekizumab
    Study participants will receive a bimekizumab dose which is dependent on their weight.

Primary Outcome Measure

Plasma bimekizumab concentrations over the Initial Treatment Period [ Time Frame: Up to Week 16 ]

Central Contacts

Related Studies